The A2AR antagonist AZD4635 has been studied as monotherapy in CRC murine models CT26 and MC38 and has been shown to slow tumor growth by 44% and 73%, respectively, with improvements to 73% and 91% with the addition of anti-PD-1 therapy [284]. This evidence concerns the gene PDCD1 and neoplasm.